Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Regulus Therapeutics 10628 SCIENCE CENTER DRIVE SAN DIEGO CA 92121 USA

P: 858-202-6300

Description:

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.

Key Statistics

Overview:

Market Capitalization, $K 14,440
Shares Outstanding, K 20,825
Annual Sales, $ 70 K
Annual Net Income, $ -48,710 K
Last Quarter Sales, $ 20 K
Last Quarter Net Income, $ -5,010 K
60-Month Beta 1.89
% of Insider Shareholders 10.70%
% of Institutional Shareholders 44.96%
Float, K 18,597
% Float 89.30%

Growth:

1-Year Return -64.79%
3-Year Return -97.97%
5-Year Return -99.67%
5-Year Revenue Growth -99.64%
5-Year Earnings Growth -3.52%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/14/19
Earnings Per Share ttm -2.77
EPS Growth vs. Prev Qtr 3.23%
EPS Growth vs. Prev Year 80.78%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-12 on 10/04/18

RGLS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -0.51
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) 0.00
Return-on-Assets (Before Tax) -100.18
Profit Margin % -69,585.71
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 191.47
Price/Cash Flow N/A
Price/Book 2.90
Book Value/Share 0.23
Interest Coverage -19.79
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar